👋 Hey, let’s get into it. California’s highest court says drugmakers cannot be sued simply for failing to bring a potentially safer replacement to market sooner.

In a 6-1 ruling, the court sided with Gilead against tens of thousands of HIV patients who alleged the company delayed TAF medicines to protect profits from older TDF drugs. Patients may still bring conventional product-liability claims involving defective drugs, but manufacturers have no separate legal duty to commercialize an improved alternative faster.

In plain English: Pharma is not legally required to hit “publish” on Drug 2.0.

Programming note: BioNucleus will take a short break beginning August 13, but we’ll be back with a new edition on August 25.

✂️ Pfizer Adds $2.5B in Cuts as Seagen ADC Triggers $3.8B Write-Down
Pfizer found another $2.5 billion to cut, then found $3.8 billion it could no longer defend on the balance sheet. The new savings target spans commercial, R&D, support functions, and manufacturing through 2029. The write-down is tied to sigvotatug vedotin, a Seagen-origin ADC that failed to improve overall survival in a Phase 3 lung-cancer trial. Pfizer is not writing another $3.8 billion check. It is lowering the drug’s recorded value after the setback. The company is still evaluating it elsewhere, but this is expensive evidence that not every piece of the $43 billion Seagen acquisition will deliver as planned.

💰 KKR Takes Medtech Manufacturer Integer Private for $5.7B
KKR agreed to acquire Integer Holdings for $127 per share in cash, valuing the medical-device manufacturer at roughly $5.7 billion including debt. Integer employs about 11,000 people and helps develop and manufacture products used in cardiovascular care, neuromodulation, and cardiac-rhythm management, making this a private-equity bet on medtech’s picks-and-shovels layer. The price represents a 51.8% premium to Integer’s closing price before it announced a strategic review. The deal still needs shareholder and regulatory approval and is expected to close by year-end.

🤖 Pathos AI Makes Two Oncology Bets Worth More Than $2B
Pathos AI went oncology shopping twice in two days. It paid $125 million upfront for ex-Greater China rights to JSKN016, Alphamab’s Phase 3 TROP2/HER3 bispecific ADC, with up to $2.093 billion more tied to milestones. Pathos also struck a co-exclusive deal with AstraZeneca for AZD4241, a preclinical oral program designed to degrade estrogen receptors in certain breast cancers; terms were undisclosed. Its Foundry platform helped prioritize the opportunities but did not invent the molecules. Now comes the useful test: whether AI-guided asset selection can improve clinical execution, not just PowerPoint execution.

🏭 STERIS Plans a $600M North Carolina Manufacturing Hub
STERIS plans to invest $600 million in a 600,000-square-foot manufacturing and distribution hub in Sanford, North Carolina, creating 335 jobs. The phased campus will make and distribute cleaning and sterilization products, with laboratory and R&D space included. Some existing chemistry work will shift from St. Louis and Minnesota, so this is part expansion and part consolidation. It’s also a reminder that reshoring is not limited to biologics plants. Someone still has to manufacture the products that keep all those shiny new facilities clean. Operations are expected to begin in phases over the next two to three years.

🏆 Gilead’s PrEP Business Crosses $1B in Quarterly Sales
Gilead’s HIV prevention franchise topped $1 billion in quarterly sales for the first time, more than doubling year over year. Twice-yearly Yeztugo generated $232 million, while the remainder came primarily from daily Descovy used for prevention. Gilead said more than 70% of eligible early Yeztugo users returned for their second six-month injection. That is a promising persistence signal, but not a mature long-term retention rate. Still, with the broader U.S. PrEP market growing about 14%, Gilead is showing that two shots a year can produce ten digits a quarter.

😑 AstraZeneca-BMS Megadeal Rumor Starts Unraveling
An unnamed senior source said the drugmakers were never in merger talks, puncturing a rumor that briefly rattled nearly $400 billion of pharma.

🪓 Pfizer Cuts Two Obesity Programs After Its $10B Metsera Buy
Pfizer cut oral GLP-1 MET-224o and GIP antagonist PF-07976016, trimming two obesity programs less than a year after its $10 billion Metsera acquisition.

🫁 Merck’s $10.8B Immunology Bet Scores a Win and a Loss
Merck’s tulisokibart met hidradenitis targets but failed in systemic sclerosis lung disease, narrowing the expansion thesis behind its $10.8 billion Prometheus acquisition.

⚖️ Lilly and FDA Fight Over Whether Retatrutide Is a Biologic
Lilly’s unresolved fight to classify retatrutide as a biologic could shape its filing route and exclusivity before a planned early-2027 submission.

😎 Charles River Sees Early Signs of a Biotech Research Rebound
Charles River raised its profit outlook as preclinical bookings hit a four-year high, offering an early signal that biotech research demand is improving.

📈 Attovia Jumps 24% After Its Upsized $289M IPO
Attovia shares jumped 24% in their Nasdaq debut after the anti-itch biotech priced an upsized $289 million IPO at $17 per share.

⚠️ Lisata Cuts 72% of Staff and Sues Kuva
Lisata cut 72% of staff and sued Kuva after their merger collapsed, leaving liquidation among the biotech’s stated strategic options.

Lilly and Novo both raised their 2026 outlooks this week…but only one got applause.

Lilly’s second-quarter revenue jumped 48% to $22.97 billion. Mounjaro produced $9.94 billion and Zepbound another $4.93 billion, giving its two tirzepatide brands nearly $14.9 billion, or about 65% of company sales. Lilly raised full-year revenue guidance to $85 billion to $87 billion. Its new obesity pill, Foundayo, generated $98 million, below expectations, but management said injectables still account for roughly three-quarters of new patient starts. Convenience matters. Apparently, needles remain acceptable when the results are good.

Novo delivered a respectable quarter by almost any standard…except Lilly’s. Adjusted sales reached about $12.1 billion, with its diabetes-and-obesity portfolio producing roughly $9.2 billion. Oral Wegovy generated about $497 million, slightly below expectations, but passed five million cumulative prescriptions and captured roughly 90% of the U.S. oral-obesity market. Novo raised its constant-currency outlook to a range of down 6% to flat. Its shares still fell.

The pipeline did not improve the mood. In REIMAGINE-4, CagriSema produced 15.2% weight loss versus 15.8% for tirzepatide at 68 weeks. It met the trial’s weight-loss noninferiority goal but delivered a smaller HbA1c reduction. These are top-line results, and Novo has separately submitted CagriSema for U.S. obesity review. The company also ended development of monlunabant after judging its safety profile unacceptable, adding another setback to its $1.075 billion Inversago acquisition.

The sales totals are not perfectly comparable because they span different brands, indications, and currencies. But the direction is now clearer. Lilly owns the current momentum, while Novo has a promising pill and a successor problem. Wall Street is no longer asking whether these companies can sell GLP-1s…it’s grading who looks best for the next lap.

That is how much Bank of America CEO Brian Moynihan says the company now spends a year on GLP-1 medicines for its roughly 211,000 employees, about one-eighth of its healthcare budget. He calls it a good investment. The pharmacy bill arrives now…the hoped-for health savings come later.

Here’s what biotech Redditors are talking about:

🤲 Bare Hands Send Reddit Into a GMP Spiral
A short video on r/biotech appears to show someone handling pills with bare hands before feeding them into packaging equipment. The quality crowd immediately raised contamination and worker-exposure concerns. Others thought the hand movements looked less like pharma manufacturing and more like a DJ set. The clip leaves out crucial context, including the product, location, and whether any rule was actually broken. Gloves are also only one small piece of GMP. Still, every quality professional watching probably started sweating before it ended.

✌️ Why Does It Feel Like Everyone Is Leaving Biotech?
One Redditor asked why experienced professionals seem eager to leave biotech, and the replies became an unofficial industry exit interview: layoffs, burnout, expensive hubs, uneven pay, and shaky work-life balance. Several wished they had gone to medical school. Others quickly supplied the counterargument: debt, residency, trauma, reimbursement battles, and physician burnout. It’s not proof of a mass exodus, but it captures the mood right now. Every career looks greener when your company is cutting headcount.

🥬 Michigan Cyclospora Outbreak Tops 12,000 Cases; Two Deaths Reported
Michigan, the epicenter of the current U.S. Cyclospora surge, has reported 12,218 probable and confirmed cases, 193 hospitalizations, and two associated deaths.

💉 mRNA Vaccine Trial Starts as U.S. Pledges $242M for Ebola Response
Moderna dosed the first volunteer in a Bundibugyo Ebola vaccine trial as Washington pledged another $242 million to the fast-growing Congo response.

🥼 Hinge Health Will Buy Cylinder for $105M
Hinge Health, apparently not a dating app for doctors, will buy Cylinder for $105 million, adding digestive care and roughly two million covered lives.

🤖 QuantHealth Wants to Simulate Trials Before Patients Enroll
QuantHealth raised a $45 million Series B to expand software that simulates clinical-trial designs and patient populations before enrollment begins. The company says customers have run more than 600 virtual trials across 30 indications, with predictive accuracy of up to 90%. Those are company-reported claims, and a simulation still cannot replace an actual trial. But the premise is attractive: fail in silico before failing much more expensively in vivo. External validation is the next test.

🧫 August 6, 1881: The Patron Saint of Contaminated Petri Dishes Is Born
Alexander Fleming was born near Darvel, Scotland, on this day in 1881. In 1928, he noticed that mold contaminating a bacterial culture inhibited growth and named the substance penicillin. Fleming later shared the 1945 Nobel Prize with Howard Florey and Ernst Boris Chain, whose teams helped turn the observation into a usable medicine. Fleming also warned that improper antibiotic use could select for resistant microbes. One of medicine’s greatest breakthroughs began with contaminated labware, then became a lesson in stewardship.

Bank of America CEO Brian Moynihan calls the company’s $250 million annual GLP-1 bill a good investment. Maybe he is already factoring in fewer catered lunches, untouched office snacks, and employees working straight through noon.

Soon, the break room will contain nothing but a water cooler, wax fruit, and a note from HR: “Hungry? Sign up here for GLP-1s.”

The medication may cost $250 million, but at least lunch is finally under budget.

That’s all for today. See you Tuesday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

BioNucleus Briefing has 1,400+ combined newsletter subscriptions across email and LinkedIn, reaching scientists, founders, investors, operators, and other biotech and pharmaceutical professionals.

Sponsorship opportunities are available for companies offering tools, software, services, events, and other products relevant to the life-sciences industry.

Interested in sponsoring an upcoming issue? Reply to this email and let’s talk.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead